Cannabis in Cancer Care
Presented by: Donald Abrams, MD
Delta-9-tetrahydrocannabinol (THC), the main psychoactive component of cannabis, was licensed and approved for the treatment of chemotherapy-induced nausea and vomiting in 1985. Due to the significant barriers to studying the potential therapeutic effects of the parent botanical, the medical literature does not support the strong anecdotal impression that cannabis itself is effective for this indication. Cannabis is also the only antiemetic agent that is also purported to be an appetite stimulant that is also a useful attribute in patients with malignant diagnoses.
Content Access
